Subsequently, we found that CD63/81+ sEVs were abundant in pre-treatment RB eyes, particularly those with higher tumor burden, suggesting CD63/81+ sEVs are tumor-derived, showcasing their potential as biomarkers [19]. The gene discussed is CD63; the disease is retinoblastoma.